MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
Year: 2022
Type: article
Source: Blood
Authors: Amrita Y. Krishnan, Salomon Manier, Evangelos Terpos, Saad Usmani, Josephine Khan, Rachel Pearson, Suzette Girgis, Yue Guo, Dana McAleer, Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk
Institutions: City Of Hope National Medical Center, City of Hope, Université de Lille, National and Kapodistrian University of Athens, Memorial Sloan Kettering Cancer Center, Janssen (United Kingdom), Janssen (Belgium), Janssen (Germany), Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310159950